Recognizing autoimmune encephalitis as a cause of seizures
Treating cause and not effect
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published April 12, 2019.
Article Versions
- Previous version (April 12, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Jeffrey W. Britton, MD and
- Josep Dalmau, MD
- Jeffrey W. Britton, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Unpaid co-investigator clinical trials: -A Randomized Double Blind Placebo Controlled Study of IVIG in Patients with Voltage Gated Potassium Channel Complex Antibody Associated Autoimmune Epilepsy - Grifols Pharmaceuticals -A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experience inadequately- controlled seizures- Greenwich Pharmaceuticals - An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes - Greenwich Pharmaceuticals
NONE
NONE
NONE
NONE
Mr. and Mrs. David Hawk charitable gift for epilepsy research
NONE
NONE
NONE
NONE
NONE
NONE
- Josep Dalmau, MD
NONE
NONE
NONE
Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate
Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.
NONE
NONE
Advance Medical
NONE
NONE
NONE
NONE
-NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -Fundacio CELLEX
NONE
NONE
NONE
NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun
Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests
NONE
NONE
NONE
- From the Division of Epilepsy (J.W.B.) and ICREA and Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic (J.D.), Universitat de Barcelona, Spain; and Department of Neurology(J.D.), University of Pennsylvania, Philadelphia.
- Correspondence
Dr. Britton britton.jeffrey{at}mayo.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Alert Me
Recommended articles
-
Article
Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitisMarienke A.A.M. de Bruijn, Agnes van Sonderen, Marleen H. van Coevorden-Hameete et al.Neurology, April 12, 2019 -
Article
Immunoadsorption therapy in autoimmune encephalitidesMüjgan Dogan Onugoren, Kristin S. Golombeck, Corinna Bien et al.Neurology - Neuroimmunology Neuroinflammation, February 26, 2016 -
Article
Cryptogenic NORSEIts distinctive clinical features and response to immunotherapyTakahiro Iizuka, Naomi Kanazawa, Juntaro Kaneko et al.Neurology: Neuroimmunology & Neuroinflammation, September 25, 2017 -
Article
Neuronal antibody prevalence in children with seizures under 3 yearsA prospective national cohortJoseph D. Symonds, Teresa C. Moloney, Bethan Lang et al.Neurology, July 20, 2020